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Abstract 
We propose to disclose first degree analogous features between cancer and infectious dis-
eases and to find out whether these similarities are superficial and negligible, due to the use of 
the same bodily pathways by the two categories of disease or if they represent significantly 
parallel characteristics. We have found several primary analogous features, predominantly 
regarding pathways of spread, but to some extent also concerning the interaction with the 
immune system. Some of the implications to our hypothesis are probably available in the 
recent literature, at the experimental or clinical levels. For example endostatin, an angiogenic 
inhibitor has been used to prevent promotion of metastasis in cancer and to reduce granu-
lomas formation in schistosomiasis. An ECFR antagonist employed to restrain bronchial 
vessels proliferation in pseudomonas infection, has also been used for the treatment of lung 
cancer. 
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Introduction 
Cancer and infectious diseases are totally distinct 
categories of ailments. But at times they may present 
with  similar  symptoms  and  signs  [1,  2].  They  are 
however treated with different modalities of therapy. 
Usually, infectious diseases do not carry the gloomy 
outlook  of  malignant  tumors,  although  an  infection 
may be fatal or develop at the end of treatment of a 
cancer. 
When searching for the similarities, they seem to 
be found superficially in several aspects of the two 
categories  of  illnesses.  Prominent  among  these  are 
parallel immediate means of spread [3, 4], some as-
pects of the role of immunity [5] and the characteris-
tics of terminal events occurring in these diseases. 
We  have  reviewed  the  analogous  features  of 
these two categories of diseases, in an attempt to find 
out whether they are absent or negligible, if they pre-
sent  with  similar  mechanisms  or  if  they  possess 
common  properties.  We  have  attempted  to  refrain 
from  mentioning  strictly  different  features  which 
represent the usual occurrence. 
Pathogenic agents and genes 
a priori, one should not be able to find any simi-
larity between genes involved in carcinogenesis and 
microbes. The analogy, if any, may be limited to the 
fact that both oncogenes and pathogenic microorgan-
isms  cause  morbidity  and  mortality,  though  in 
markedly different ways. However, oncogene activa-
tion is inhibited by that of tumor suppressor genes, in 
a way which reminds superficially of the normal flora 
which checks the growth of pathogens at several body 
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sites [6, 7]. When tumor suppressor genes are over-
whelmed by a mutation (deletion), the burst of tumor 
growth may evoke an association with the infectious 
morbidity  that  occurs  when the normal flora is de-
stroyed  by  wide  spectrum  antibiotics  [7].  Tumor 
suppressor  genes,  by  promoting  growth  inhibition, 
remind in a way of the normal flora, which by prolif-
erating on the skin, gastrointestinal tract and vagina, 
prevents  the  outgrowth  of  pathogenic  microorgan-
isms. 
A  further  parallel  feature  is  that  of  oncogenic 
viruses  and  bacteria  which  promote  an  infectious 
disease on the one hand and are capable of causing 
cancer on the other hand, following a long latent pe-
riod [3, 8]. 
Spread and dissemination 
Mechanisms of spread at the molecular level are 
as different as possible in the two categories of disease 
discussed.  Nevertheless,  the  primary  aspects  of  the 
modalities of spread seen in malignant tumors paral-
lel almost fully those described in infectious diseases 
[3, 4, 9]. 
Local invasion at the site of the primary tumor, 
in continuity, is an important property of malignancy, 
as it is necessary for the tumor to reach tissue planes 
that will promote further dissemination [4]. In infec-
tions, proliferation and spread at the portal of entry 
may at times represent the only mode of dissemina-
tion of the microbe. But often, it is followed in cancer 
as well as in infectious diseases by one or more of the 
mechanisms  of  spread:  lymphatic  spread,  hematog-
enous dissemination, spread through body cavities as 
well as along nerves [3, 4]. These pathways support 
the dissemination of both infectious agents and tumor 
cells, even though the mechanisms involved are dif-
ferent. 
The  various  modalities  of  spread  lend  to  the 
tumor or the infection a dimension of increased illness 
severity  [3,  10].  Thus,  in  cancer,  local  invasiveness, 
usually followed by metastasis, will indicate a low or 
nil potential for cure [4]. Hematogenous spread of a 
microbe, culminating in septicemia, will carry out a 
severe  morbidity  and  in  the  case  of  Gram  negative 
bacilli a very high mortality [11]. 
The above description is very suggestive of an 
analogy based on the use by both categories of dis-
eases of the same bodily pathways. And in fact, the 
morphology,  together  with  the  activation  of  similar 
adhesion  molecules,  or  the  epithelial  mesenchymal 
transition,  may  explain  the  resemblance  of  the 
spreading mechanisms. The similarity is indeed high, 
pending  our  restriction  to  the  primary  features  of 
spread and attempting not to bring out the marked 
difference between the two sorts of disease. 
Role of immunity 
The  strongest  evidence  for  the  existence  of 
“immune surveillance” is the increased frequency of 
cancer  in  immunosuppressed  patients.  However, 
these patients suffer predominantly from lymphomas 
[11].  
Patients with immune suppression are at a high 
risk  of  developing  opportunistic  infections  [12]. 
However most cancer patients are immunocompetent 
[12]  and  most  infectious  diseases  arise  in  basically 
healthy individuals and are caused by common viru-
lent microbes [13]. Thus, tumor cells have to set up 
mechanisms  to  evade  the  immune  system  [14,  15]. 
Similarly,  infectious  agents  have  to  overcome  the 
body  barriers,  as  well  as  the  immune  mechanisms 
[14]. 
Both categories of diseases may have in common 
loss or reduced expression of class I MHC molecules, 
thus  escaping  attacks  by  cytotoxic  T-cells  [16].  We 
may find antigen masking with both tumor cells and 
infection that will render the cell or pathogen inac-
cessible to the immune system (Clostridium difficile, 
salmonella  typhi).  Both  may  use  antigen  variation: 
cancer cells will outgrow selectively antigen negative 
variants  to  prevent  access  to  immune  mechanisms 
[17]. 
Thus there are a few similarities in the way these 
two types of disease manipulate the immune system 
to their advantage. However, the immune system has 
the capacity to fight numerous infectious agents and 
cancer  cells  using  a  vast  array  of  mechanisms.  But 
again, the emphasis in this review is on the common 
denominators and not on the differences between the 
types of disease. 
Treatment and complications 
Chemotherapy, in its most simple sense, is the 
treatment  of  a  disease  by  chemicals,  especially  for 
killing microorganisms or cancerous cells. This term is 
now  used  predominantly  in  oncology  for  the  treat-
ment of malignant diseases [18]. 
At times, a cancer develops during the process of 
an infectious disease. Most prominent in this context 
are  neoplasms  occurring  at  some  point  in  relation 
with a viral disease [8, 19].  
Infection by HTLV-1, a retrovirus, may lead, af-
ter some delay, to adult T-cell leukemia/lymphoma 
[20].  
The  other  oncogenic  viruses  are  mainly  DNA 
viruses  and  include  the  human  papillomavirus,  the 
cause of genital warts and of cervical, anal and oro-




hepatitis C virus (a RNA virus), are considered the 
etiological  factors  of  most  hepatocellular  cancers  in 
man [19, 23, 24]. Epstein-Barr virus has been associ-
ated with diffuse large B-cell lymphoma,  mainly in 
relation  with  immune  suppression;  with  endemic 
Burkitt lymphoma and with a fraction of the sporadic 
form  of  this  tumor;  with  a  proportion  of  Hodgkin 
lymphoma; with nasopharyngeal carcinoma and with 
a  small  group  of  gastric  cancer  [25-27].  Kaposi  sar-
coma-related herpes virus (HHV-8) has been associ-
ated with  Kaposi sarcoma, multicentric Castleman's 
disease  and  with  body  cavities-related  large  B-cell 
lymphoma [28]. 
In  most  oncogenic  viral-related  neoplasms  a 
chronic inflammation  precedes the malignant trans-
formation  and  represents  a  chronic  persistent  viral 
infection.  When  examining  the  association  between 
chronic inflammation and malignant transformation, 
these persistent viral infections have been listed to-
gether with celiac disease, Crohn's disease as well as 
autoimmune diseases, as conditions that may precede 
the development of malignant diseases. 
In  the  last  decades,  a  few  bacterial  infections 
have  demonstrated  a  link  with  cancer.  The  most 
firmly established relationship is between Helicobac-
ter pylori and low-grade mucosa associated lymphoid 
tissue (MALT) lymphoma, as well as with gastric car-
cinoma  [29,  30].  An  association  between  low-grade 
MALT-oma  of  the  skin  and  infection  by  Borrelia 
burgdorferi has been shown, at best, to be limited to 
European  countries  [31,  32].  Lately,  low-grade 
MALT-lymphoma  of  the  ocular  adnexae  (eyelid, 
conjunctiva,  orbit,  lacrimal  tracts  and  glands)  has 
been  tentatively  connected  with  infection  by  Chla-
mydophilia psittaci [33]. Thus, a microbial infection 
may at times also deteriorate into a malignant tumor. 
On the other hand, cancer patients often develop 
an  opportunistic  infection  that  may  be  fatal.  This 
event may be a complication of the neoplasm or be 
indirectly  due  to  immune  suppression  that  follows 
cancer therapy. Thus, the health of a cancer patient 
may deteriorate due to an opportunistic, perhaps fatal 
infection.  This  analogy  between  malignant  tumors 
and infection may be superficial, but it however be-
comes more significant as the transformation leads to 
death. 
Tumor progression will lead as a rule to tumor 
heterogeneity.  The  appearance  of  neoplastic  sub-
clones will promote tumor aggressiveness, invasive-
ness  and  increased  metastatic  potential  which  may 
anticipate the patient death [34]. 
Microbial  infections,  if  partially  treated  or  de-
veloping  in  a  weakened  or  immunosuppressed  pa-
tient,  will  tend  to  become  persistent.  The  microbes 
may  acquire  additional  factors  of  invasiveness.  The 
infectious disease will then become more aggressive, 
with  increased  potential  for  septicemia  and  patient 
death [5]. 
In both branches of the analogy the agent (tumor 
cell or microbe) is transformed into a more aggressive 
player in the development of the disease. This lends 
the  parallel  features  of  the  cancer  and  infection  a 
higher degree of significance. 
Miscellaneous 
The peculiar mother-fetus relationship has been 
likened with the association host-cancer. Similarly to 
the fetus, the tumor cells may hide the expression of 
the MHC type I molecules and refrain from express-
ing  foreign  (non-self)  antigens  [35].  An  analogous 
behavior, though not identical, may occur with infec-
tious agents. Patients with typhoid fever may develop 
a  carrier  state  following  the  acute  infection.  In  this 
condition, the Salmonella typhi will grow unharmed 
in the gallbladder or urinary bladder and will be shed 
occasionally to contaminate innocent  individuals. A 
hydatid cyst is a further example of a similar occur-
rence. 
However rare and mainly limited to melanoma, 
transplacental metastasis has been described [35-37]. 
Transplacental infections transferred from mother to 
fetus, are probably more frequent [35].  
Male  circumcision  is  presented  to  highlight  a 
therapeutic aspect of a possible analogy between the 
two groups of ailments. Circumcision is carried out 
for  traditional  reasons,  the  significance  of  which  is 
unclear,  but  may  be  related  to  hygiene.  This  tradi-
tional  intervention  mostly  resolves  two  problems, 
infectious illnesses, which are now known to include 
prevention  of  HPV  contamination  by  the  male  and 
directly, reduction of the rate of penile squamous cell 
carcinoma. 
Conclusions 
We  have  described  several  analogies  between 
cancer and infectious diseases, some stronger, others 
less  so.  The  more  marked  similarities  concern  the 
mechanism of spread and dissemination, and the as-
sociation with the immune system. This comes as no 
surprise as both tumor cells and infectious agents are 
considered at some point as “foreign” (non-self) in-
vaders. 
Consequently, and restricting our discussion to 
the most primary features of the comparison, we offer 
our  hypothesis  that  cancer  and  infectious  diseases 
have  some  descriptive  and  perhaps  also  some 
"mechanistic" features in common. If the hypothesis 




ries of disease have several aspects in common, per-
haps including therapeutic and preventing traits. In 
fact, interferons have been used as a treatment of both, 
infectious  diseases  and  cancer,  most  strikingly  for 
HBV infection and for the prevention of liver cancer 
related with HBV. 
Endostatin,  an  anti-angiogenic  factor  has  been 
used to reduce the volume of granulomas in schisto-
somiasis. This agent has also been employed for the 
inhibition  of  neoangiogenesis  of  cancer  and  against 
the subsequent promotion of metastasis [38]. 
Pseudomonas  aeruginosa  induces  VEGF  syn-
thesis,  thus  causing  bronchial  vessels  proliferation. 
The effect due to this Gram-negative bacillus has been 
prevented  by  an  EGFR-antagonist  [39],  which  may 
play  a  role  in  the  treatment  of  non-small  cell  lung 
cancer. 
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